187 related articles for article (PubMed ID: 22864732)
1. Fimasartan, a novel angiotensin II receptor antagonist.
Kim JH; Lee JH; Paik SH; Kim JH; Chi YH
Arch Pharm Res; 2012 Jul; 35(7):1123-6. PubMed ID: 22864732
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers.
Yi S; Kim TE; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Cardiovasc Pharmacol; 2011 Jun; 57(6):682-9. PubMed ID: 21394036
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
[TBL] [Abstract][Full Text] [Related]
5. A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension.
Lee JH; Yang DH; Hwang JY; Hur SH; Cha TJ; Kim KS; Kim MH; Chun KJ; Cha GS; Hong GR; Lee SG; Kim DS; Kim DI; Chae SC
Clin Ther; 2016 Jun; 38(6):1485-1497. PubMed ID: 27161546
[TBL] [Abstract][Full Text] [Related]
6. Fimasartan.
Am J Cardiovasc Drugs; 2011 Aug; 11(4):249-52. PubMed ID: 21740078
[TBL] [Abstract][Full Text] [Related]
7. Fimasartan: A New Angiotensin Receptor Blocker.
Lee HY; Oh BH
Drugs; 2016 Jul; 76(10):1015-22. PubMed ID: 27272555
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
[TBL] [Abstract][Full Text] [Related]
9. Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial.
Kang MG; Kim KI; Ihm SH; Rhee MY; Sohn IS; Lee HY; Park S; Jeon ES; Song JM; Pyun WB; Sung KC; Kim MH; Kim SH; Kim SY; Kim SJ; Kim EJ; Shin J; Lee SY; Chun KJ; Jeong JO; Chae SC; Yoo KD; Choi YJ; Park YH; Kim CH
Trials; 2019 Jul; 20(1):389. PubMed ID: 31262348
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study.
Youn JC; Ihm SH; Bae JH; Park SM; Jeon DW; Jung BC; Park TH; Lee NH; Song JM; Yoon YW; Shin ES; Sung KC; Jung IH; Pyun WB; Joo SJ; Park WJ; Shin JH; Kang SM
Clin Ther; 2014 Oct; 36(10):1412-21. PubMed ID: 25092393
[TBL] [Abstract][Full Text] [Related]
11. The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review.
Borghi C; Cicero AF
High Blood Press Cardiovasc Prev; 2012 Mar; 19(1):19-31. PubMed ID: 22670584
[TBL] [Abstract][Full Text] [Related]
12. Influence of hepatic dysfunction on the pharmacokinetics and safety of fimasartan.
Kim CO; Lee HW; Oh ES; Seong SJ; Kim DY; Lee J; Ahn SH; Yoon YR; Cho CM; Park MS
J Cardiovasc Pharmacol; 2013 Dec; 62(6):524-9. PubMed ID: 24084213
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study.
Park JB; Sung KC; Kang SM; Cho EJ
Am J Cardiovasc Drugs; 2013 Feb; 13(1):47-56. PubMed ID: 23344912
[TBL] [Abstract][Full Text] [Related]
14. Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling.
Bulitta JB; Paik SH; Chi YH; Kim TH; Shin S; Landersdorfer CB; Jiao Y; Yadav R; Shin BS
Eur J Pharm Sci; 2017 Sep; 107():32-44. PubMed ID: 28599987
[TBL] [Abstract][Full Text] [Related]
15. Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension.
Kim SY; Joo SJ; Shin MS; Kim C; Cho EJ; Sung KC; Kang SM; Kim DS; Lee SH; Hwang KK; Park JB
Medicine (Baltimore); 2016 May; 95(22):e3764. PubMed ID: 27258507
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study.
Oh GC; Joo KW; Kim MA; Choi DJ; Kim YJ; Lee HY
Drug Des Devel Ther; 2020; 14():1341-1349. PubMed ID: 32308367
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia.
Rhee MY; Ahn T; Chang K; Chae SC; Yang TH; Shim WJ; Kang TS; Ryu JK; Nah DY; Park TH; Chae IH; Park SW; Lee HY; Tahk SJ; Yoon YW; Shim CY; Shin DG; Seo HS; Lee SY; Kim DI; Kwan J; Joo SJ; Jeong MH; Jeong JO; Sung KC; Kim SY; Kim SH; Chun KJ; Oh DJ
BMC Pharmacol Toxicol; 2017 Jan; 18(1):2. PubMed ID: 28057081
[TBL] [Abstract][Full Text] [Related]
18. Antiatherosclerotic effects of the novel angiotensin receptor antagonist Fimasartan on plaque progression and stability in a rabbit model: a double-blind placebo-controlled trial.
Lee JY; Lee CW; Kim WJ; Ahn JM; Park DW; Kang SJ; Lee SW; Kim YH; Son WC; Jung S; Park SW; Park SJ
J Cardiovasc Pharmacol; 2013 Aug; 62(2):229-36. PubMed ID: 23615162
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological properties and clinical efficacy of the long-active angiotensin receptor blocker (ARB) irbesartan].
Ariyoshi Y; Mizumoto K
Nihon Yakurigaku Zasshi; 2009 May; 133(5):275-80. PubMed ID: 19443965
[No Abstract] [Full Text] [Related]
20. Comparison of the Effect of Fimasartan versus Valsartan on Blood Pressure Variability in Acute Ischemic Stroke: A Double-Blind Randomized Trial.
Shin DH; Song S; Lee YB
Cardiovasc Ther; 2019; 2019():7836527. PubMed ID: 31772615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
